Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma

David S. Hong, Razelle Kurzrock, Jennifer J. Wheler, Aung Naing, Gerald S. Falchook, Siqing Fu, Kevin B. Kim, Michael A. Davies, Ly M. Nguyen, Goldy C. George, Lucy Xu, Robert Shumaker, Min Ren, Jennifer Mink, Cynthia Bedell, Corina Andresen, Pallavi Sachdev, James P. O’Brien, and John Nemunaitis

Abstract

Purpose: This “3+3” phase I study evaluated the safety, biologic, and clinical activity of lenvatinib, an oral multikinase inhibitor, in patients with solid tumors.

Experimental Design: Ascending doses of lenvatinib were administered per os twice daily in 28-day cycles. Safety and response were assessed for all patients. Angiogenic and apoptotic factors were tested as possible biomarkers in an expanded melanoma cohort.

Results: Seventy-seven patients were treated in 3 cohorts: 18 with intermittent twice-daily dosing (7 days on, 7 days off) of 0.1–3.2 mg; 33 with twice-daily dosing of 3.2–12 mg; and 26 with twice-daily dosing of 10 mg (expanded melanoma cohort). Maximum tolerated dose was established at 10 mg per os twice daily. Prominent drug-related toxicities included hypertension (43%), fatigue (42%), proteinuria (39%), and nausea (25%); dose-limiting toxicities included hypertension, fatigue, and proteinuria. Twelve patients (15.6%) achieved partial response (PR, n = 9) or unconfirmed PR (uPR, n = 3), and 19 (24.7%) achieved stable disease (SD) ≥23 weeks. Total PR/uPR/SD ≥23 weeks was 40.3% (n = 31). Responses (PR/uPR) by disease were as follows: melanoma, 5 of 29 patients (includes 1 patient with NRAS mutation); thyroid, 3 of 6 patients; pancreatic, 1 of 2 patients; lung, 1 of 1 patients; renal, 1 of 1 patients; endometrial, 1 of 4 patients; and ovarian, 1 of 5 patients. AUC0–24 and Cmax increased dose proportionately. In multivariate Cox proportional hazard model analyses, increased baseline systolic blood pressure and decreased angiopoietin-1 ratio (2 hours:baseline) were associated with longer progression-free survival (PFS) in the expanded melanoma cohort (P = 0.041 and P = 0.03, respectively).


Introduction

Angiogenesis is required for tumor growth, progression, and metastasis, making it a logical target for antitumor drug development. Several growth factors are positive regulators of angiogenesis, including vascular endothelial growth factor (VEGF), basic and acidic fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF). Each of these factors signal through specific transmembrane tyrosine kinase receptors: VEGFRs 1 and 2 [FMS-like tyrosine kinase (FLT-1) and fetal liver kinase 1 (kinase insert domain receptor (FLK-1/KDR)], FGF, and PDGFR (1–3).

Lenvatinib is an oral, multi-tyrosine kinase inhibitor active against RET, VEGFR1–3, FGFR1–3, KIT, and PDGFRα (4–6). Lenvatinib inhibits VEGF-driven human umbilical vein endothelial cell proliferation and tube formation and significantly inhibits tumor growth in various murine tumor models, including human lung (H146) and breast cancer (MDA-MB-231) mouse xenograft models (4, 5). On the basis of a population pharmacokinetics (PK)/pharmacodynamics (PD) analysis of lenvatinib, agents that modify gastric pH levels do not have a significant effect on the absorption of lenvatinib (Eisai, data on file). Earlier studies have shown that lenvatinib exposure is neither affected by food intake (7) or coadministration of CYP3A4 inhibitors and inducers (8, 9). Lenvatinib is rapidly and well absorbed: it is also extensively metabolized, with predominant excretion in feces, and to a smaller extent in urine (10). The primary objectives of this study were to identify the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and the PK profile of lenvatinib.

Materials and Methods

Ethics

The study followed the International Conference on Harmonization of Technical Requirements for Registration of...
Pharmaceuticals for Human Use guidelines and local Independent Ethics Committee standards. The study was approved by the Institutional Review Boards of The University of Texas MD Anderson Cancer Center and the Mary Crowley Cancer Research Center. All participants provided written informed consent prior to participation in the study.

Patients

Major inclusion criteria were age ≥18 years, histologic and/or cytologic diagnosis of a solid tumor/lymphoma not amenable to standard therapy, Eastern Committee Oncology Group (ECOG) performance status of ≤1, and adequate hematologic (hemoglobin ≥9 g/dL, neutrophils ≥1.5 × 10⁹/L, platelets ≥100 × 10⁹/L), hepatic (serum bilirubin ≤1.5 mg/dL and other liver parameters ≤3 × upper limit of normal (ULN)), and renal (serum creatinine ≤1.5 × ULN and creatinine clearance ≥60 mL/minute) function. Exclusion criteria included poor cardiac function, unstable ischemic heart disease, poorly controlled hypertension, and prolongation of the QT/QTc interval calculated using the Fridericia method (QTcF interval >450 msec for men or >470 msec for women). Patients who were pregnant, had untreated or unstable metastases to the central nervous system, or required chronic use of full-dose aspirin or nonsteroidal anti-inflammatory drugs were also excluded. Additional inclusion criteria for the expanded melanoma cohort included a histologic or cytologic diagnosis of advanced or metastatic melanoma untreated by standard therapies, presence of melanoma lesions amenable to biopsy and willingness to undergo biopsies of malignant and adjacent nonmalignant tissue pretreatment and at the end of cycle 1.

Study design

This open-label phase I study was conducted using a modified “3+3” dose-escalation design, which was adapted on the basis of observed toxicities. Lenvatinib was administered orally as 0.1, 1, and 10 mg tablets. The study had two schedules. Schedule 1 (cohort 1) examined escalating doses of lenvatinib ranging from 0.1 to 3.2 mg administered twice daily using a schedule of 7 days on treatment followed by 7 days off. Schedule 2 (cohort 2) examined doses ranging from 3.2 to 12 mg administered twice daily by continuous daily administration. Schedule 2 was designed to supersede schedule 1, as a previous phase I study had indicated that continuous dosing with lenvatinib was tolerated among patients with advanced solid tumors (11). Once the MTD was determined, the safety and tolerability of a 10-mg twice-daily dose was tested in an expanded melanoma cohort (cohort 3) composed of 26 patients with refractory melanoma. A 28-day treatment period constituted one treatment cycle. Only DLTs during the first 28 days of therapy (cycle 1) were assessed for dose-escalation purposes.

Following the initial dose for each of the first 2 cohorts, subsequent dose levels were selected according to an accelerated study design and toxicity-adapted model (12). There was an accelerated dose-escalation phase (only during schedule 1) and a standard dose-escalation phase. In the accelerated phase, a higher dose level could only be opened for patient accrual after 1 patient at the current dose level completed cycle 1 with no drug-related toxicity exceeding grade 1 (except alopecia, lypemohnia, and anemia). Dose increases were in 100% increments until the first patient experienced toxicity of grade ≥2. In the standard dose-escalating phase, dose increases were 50% or less depending upon the seriousness of the toxicity, and the first 3 subjects at a dose level were followed for a full cycle before the next dose level was opened. Standard dose escalation was invoked when the first patient at any dose level experienced ≥grade 2 toxicity. No intrapatient dose escalation was allowed and only DLTs experienced during the first cycle defined dose escalations. For example, if 1 of 3 patients experienced a DLT during the first cycle, an additional 3 patients were to be treated at that dose level. If no additional DLT was observed at the expanded dose level (i.e., 5 of 6 patients did not experience DLT during the first cycle), dose escalation continued. If more than 1 of the 6 patients experienced DLT during the first cycle of therapy at any dose level, dose escalation was stopped. Once the MTD was determined, the safety, tolerability, and efficacy of the MTD were tested in cohort 3, which enrolled patients with refractory melanoma.

Dose-limiting toxicity and maximum tolerated dose

A DLT was defined as any of the following: any grade ≥3 hematologic toxicity; any grade ≥3 nonhematologic toxicity (except grade 3 hypertension controllable by more intensive antihypertensive monotherapy or by adding a second antihypertensive agent); any repeated nonhematologic toxicity grade ≥2 that represented at least a two-grade increase over baseline and required reduction of the study drug dose (excluding repeated grade 3 hypertension controllable by antihypertensive treatment); or any failure to administer ≥75% of the planned dosage of lenvatinib during cycle 1 as a result of treatment-related toxicity. MTD was defined as the highest dose level at which no more than 1 of 6 patients developed a DLT.

Safety assessments: screening, baseline, and follow-up

Screening and baseline assessments included evaluation of demographic data, medical and surgical history, prior medications, a complete physical examination, vital signs, ECOG performance status, ECG, and clinical laboratory tests (including urinalysis and a serum pregnancy test), tumor history, primary diagnosis, previous treatments, and biopsies of tumor tissues.
Adverse events (AE) were recorded for patients who received at least 1 dose of lenvatinib. Safety assessments were performed in each cycle with additional weekly blood pressure monitoring. AE severity was assessed according to the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 3.0 (13). Safety assessments consisted of monitoring and recording all AEs; documenting concomitant medications; regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs and ECOG performance status, attainment of ECGs; and performance of physical examinations. An ECG was at minimum recorded for each cohort at screening, and then predose, 1 and 2 hours after dosing on day 1 of cycle 1, and at the final visit. AE screenings and laboratory tests were performed weekly or as clinically indicated.

Pharmacokinetics

Blood samples were collected for PK analysis immediately prior to the first dose of lenvatinib, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, and 24 hours following the first dose of lenvatinib on day 1 of both cycle 1 and 2 of schedules 1 and 2. In schedule 2, lenvatinib was administered once daily on day 1 of both cycle 1 and cycle 2 (in which only 1 twice-daily dose was administered on that day), then twice daily throughout the remainder of the cycles, to facilitate comparison of once-daily and twice-daily PK values. Trough samples were collected within 2 hours prior to the morning dose of lenvatinib or 12 hours after the last dose on days 8, 15, and 22 in cycle 1 (schedules 1 and 2), days 8 and 15 of all subsequent cycles (schedule 1), and day 1 of all subsequent cycles (schedules 1 and 2), as well as at the final visit.

Urine samples were collected during cycles 1 and 2 on days 1 and 8 (schedule 1) and during cycle 1 days 1 and 8 and cycle 2 day 1 (schedule 2). For both schedules, a 24-hour urine collection was performed following the dose of lenvatinib on day 1 of cycles 1 and 2. Three aliquots were collected: at 0 to 8 hours, 8 to 16 hours, and 16 to 24 hours.

Lenvatinib was extracted from plasma and urine with diethyl ether under alkaline conditions and then assayed by liquid chromatography with electrospray ionization tandem mass spectrometry. The assay range was 0.800 to 400 ng/mL for plasma and was 0.400 to 400 mg/mL for urine. Prior to the analysis, assay sensitivity, specificity, linearity, reproducibility, and stability were established. The interday accuracy (% bias) ranged from −8.9 to 4.8 and precision [% coefficient of variation (CV)] ranged from 3.0 to 17.8 in plasma and urine.

Individual lenvatinib PK parameters were calculated from plasma and urine concentration-time data using noncompartmental methods. Data analysis was conducted using WinNonlin (Phoenix version 6.2, Pharsight Corp.). Plasma concentrations reported as below the lower limit of quantitation were imputed as zero prior to the time of the peak concentration and as missing thereafter. For urine, concentrations below the lower limit of quantitation were also imputed as zero. The parameters $C_{\text{max}}$ and $T_{\text{max}}$ were determined from visual inspection of the data. AUC from 0 to 6 hours and 24 hours were determined by the linear up-down trapezoidal rule. Oral clearance (CL/F) and terminal volume of distribution were obtained using standard equations at steady state ($V_{\text{ss}}/F$) on cycle 2 day 1. Amount of lenvatinib recovered in urine was obtained from the analyte concentration and urine volumes. Using these amounts, fraction of the dose excreted in urine (fe%) was calculated.

Pharmacodynamics

Pharmacodynamic assessments were conducted and analyzed in the expanded melanoma cohort. Serum samples were collected at baseline (predose) and 2 hours after the first dose, and on days 8, 15, and 22 of cycle 1. Serum samples were tested for angiogenesis-related (MDS Pharma/Clearstone Central Lab) and apoptosis-related (Pathway Diagnostics/Quest) markers. These angiogenesis-related markers were PDGF-homodimer BB (PDGF-BB), soluble tie-2 [receptor expressed by endothelial cells (sTie-2)], angiopoietin-1 (Tie-2 ligand), soluble E-selectin (mediates leukocyte and tumor cell rolling), and soluble c-kit. The apoptosis-related markers assessed were cytochrome C (a measure of intrinsic apoptotic pathway activation) and M30 neoantigen (caspase-deaved cytokeratin-18, also a terminal apoptotic product for epithelial-derived tumors), sTie-2, angiopoietin-1, PDGF-BB, soluble e-selectin, soluble c-kit, cytochrome C, and M30 were measured by enzyme-linked immunosorbent assay. PDGF-BB was assayed by Lumines Technology using Growth Factor Buffer Reagent and a Human Custom Multiplex Antibody Bead Kit from BioSource Invitrogen. The following vital signs, clinical chemistry, and hematology parameters were also evaluated at the corresponding time points for any association with clinical outcome: diastolic BP (dBP), systolic blood pressure (sBP), lactate dehydrogenase (LDH) level, hemocrit percentage, and blood hemoglobin.

Response

Tumor measurements were assessed by clinical examination and photography (for skin lesions), computed tomography, or magnetic resonance imaging, and evaluated using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0 (14). Assessments were conducted at baseline and then approximately every 2 cycles during treatment. Responses were confirmed at a follow-up examination after ≥30 days. Tumor response was defined as complete response (CR), partial response (PR), stable disease (SD), or disease progression (PD). SD was to be maintained for ≥7 weeks and durable SD for ≥23 weeks. Clinical benefit was defined as CR + PR + durable SD ≥23 weeks.

Mutation analyses

Gene mutation analyses were conducted using DNA extracted from microdissected, archival paraffin-embedded tumor samples obtained from 26 patients in the expanded melanoma cohort. Molecular analyses were performed in the Clinical Laboratory Improvement Amendments–certified Molecular Diagnostics Laboratory at MD Anderson Cancer Center (Houston, TX) using standard operating procedures. Tumor DNA from the expanded melanoma cohort was extracted and processed independently by Sequenom to genotype DNA sequence mutations (MelaCarta panel, Sequenom) and to identify any mutation(s) associated with clinical response to lenvatinib therapy.

Statistical analyses

Demographic, safety, PK, and efficacy data were evaluated using descriptive statistics. Categorical data were summarized as frequency and percentages; continuous data were summarized as mean and standard deviation, median, or range, as appropriate. To explore the correlation of drug exposure with serum biomarkers, Pearson and Spearman correlation coefficients were calculated between PK parameters ($AUC_{0–inf}, AUC_{0–24}, C_{\text{max}}$, or $C_{\text{trough}}$) and serum biomarkers (PDGF-BB, sTie-2, soluble E-selectin,
soluble c-kit, or angiopoietin-1) at baseline (cycle 1 day 1) and at different time points compared with baseline.

Pearson and Spearman correlation coefficients were calculated between percent maximum tumor shrinkage (defined as percent change in sum of longest diameter from baseline to nadir) based on RECIST and baseline levels, as well as change from baseline levels of angiogenic and apoptotic factors.

Progression-free survival (PFS), overall survival (OS), and duration of response were calculated. The relationship between PFS and the biomarkers of angiogenesis and apoptosis were evaluated with univariate and multivariate Cox proportional hazard models. The multivariate model was selected by the forward selection method (P < 0.05) using covariates identified from univariate analysis (P < 0.1).

**Results**

**Patients**

Patients were enrolled between July 11, 2005, and August 11, 2009. Seventy-seven patients received at least 1 dose of study drug and were included in the safety (and overall) population.

In schedule 1 (twice daily, 7 days on and 7 days off), 18 subjects were enrolled (3 each in the lenvatinib 0.1, 0.2, 0.4, 0.8, 1.6, and 3.2-mg dose groups). In schedule 2 (twice daily continuous dosing), 33 subjects were enrolled: 3 subjects in the lenvatinib 0.1, 0.2, 0.4, 0.8, 1.6, 2.0, and 3.2-mg group, 7 in the 5.0-mg group, 16 in the 8.0-mg group, and 7 in the 12.0-mg group. Twenty-six subjects were included in the expanded melanoma cohort (10-mg twice daily continuous dosing).

The median age of the overall study population (n = 77) was 61.0 years (range, 28–85). Forty (52%) patients were male and 75 (97.4%) patients had a baseline ECOG performance status of ≤1. The most frequently reported tumor types were melanoma [29 (38%), colorectal [10 (13%)], thyroid [6 (8%)], and ovarian [5 (6%)]. Twenty-six (33.7%) patients had ≥3 prior chemotherapy regimens.

In the expanded melanoma cohort, the median age was 69.0 years (range, 38–85). Sixteen (61.5%) patients were male. Five (19.2%) patients had ≥3 prior chemotherapy regimens. On the basis of independent or on-site assessment, BRAF mutations were detected in 9 (34.6%) patients and NRAS mutations in 8 (30.8%) patients (Table 1). No patient with melanoma in this study had received prior V600-targeted treatment, and only 1 patient had received prior ipilimumab treatment. When this study was initiated, the currently approved BRAF-targeted therapies were still in investigational stages.

Reasons for discontinuation of study treatment included disease progression or clinical deterioration [43 (55.8%)], adverse events [17 (22.1%)], and withdrawal of consent [5 (6.5%)]. Thirteen (16.9%) patients died either during therapy or within 30 days of the last treatment. In the schedule 1 cohort (n = 18), 11 (61.1%) patients discontinued due to disease progression or clinical deterioration, and 6 (33.3%) patients due to AEs. In the schedule 2 cohort (n = 33), 17 (51.5%) patients terminated due to disease progression or clinical deterioration, and 9 (27.3%) due to AEs. In the melanoma expansion cohort, 15 (57.7%) patients discontinued due to disease progression or clinical deterioration, and 2 (7.7%) due to AEs. Of note, 8 (30.8%) patients in the expanded melanoma cohort died during therapy or within 30 days of the last treatment.

**Table 1. Baseline patient characteristics**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Melanoma expansion cohort (n = 26)</th>
<th>Entire study population (N = 77)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y**</td>
<td>Mean (SD)</td>
<td>65.5 (11.66)</td>
</tr>
<tr>
<td></td>
<td>Median</td>
<td>69.0</td>
</tr>
<tr>
<td></td>
<td>Range (38–85)</td>
<td>(28–85)</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td>Male</td>
<td>16 (61.5)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>10 (38.5)</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td>Non-Hispanic white</td>
<td>26 (100)</td>
</tr>
<tr>
<td></td>
<td>Hispanic</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>African American</td>
<td>0</td>
</tr>
<tr>
<td>EGCG status, n (%)</td>
<td>0</td>
<td>8 (30.8)</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>17 (65.4)</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>1 (3.8)</td>
</tr>
<tr>
<td>Tumor type, n (%)</td>
<td>Colorectal</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Thyroid</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Ovarian</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Endometrial</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Breast</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Melanoma</td>
<td>26 (100)</td>
</tr>
<tr>
<td></td>
<td>Lung</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Pancreatic</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Prostate</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>0</td>
</tr>
<tr>
<td>Previous antitumor treatment, n (%)</td>
<td>Chemotherapy</td>
<td>22 (84.6)</td>
</tr>
<tr>
<td></td>
<td>Radiotherapy</td>
<td>13 (50.0)</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>26 (100)</td>
</tr>
<tr>
<td>Other antitumor treatment regimens</td>
<td>18 (69.2)</td>
<td>47 (61.0)</td>
</tr>
<tr>
<td>Previous systemic treatment (chemotherapy), n (%)</td>
<td>0</td>
<td>4 (15.4)</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>8 (30.8)</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>9 (34.6)</td>
</tr>
<tr>
<td></td>
<td>≥3</td>
<td>5 (19.2)</td>
</tr>
<tr>
<td>Mutation status, n (%)</td>
<td>BRAF</td>
<td>9 (34.6)</td>
</tr>
<tr>
<td></td>
<td>NRAS</td>
<td>8 (30.8)</td>
</tr>
</tbody>
</table>

*Age calculated as (date of informed consent - date of birth + 1)/365.25.

*Mutations were assessed only in patients in the melanoma expansion cohort.

**Dose escalation, DLTs, and MTD**

As no DLTs were observed in the schedule 1 cohort, schedule 2 was initiated and dose levels of 3.2 to 12.0 mg twice daily were examined. At 12 mg, DLTs of hypertension (n = 3, all grade 3), fatigue (n = 1, grade 3), and proteinuria (n = 1, grade 2) were observed in 5 of 7 treated patients. Therefore, the previous lower dose of 8 mg twice daily was initially established as the MTD. However, an intermediate dose of 10 mg twice daily was evaluated in the expanded melanoma cohort and judged as well tolerated, with no DLTs observed in the first 6 subjects who received the 10-mg twice-daily dose. Therefore, the MTD was determined to be 10 mg twice daily.

**Safety**

The most frequently reported study drug–related toxicities were hypertension (43%), fatigue (42%), proteinuria (39%), nausea (25%), body weight reduction (25%), anorexia (25%), and diarrhea (22%; Table 2). The majority of study drug–related toxicities of all grades were observed in patients who had received dose levels ≥10 mg.
There were few treatment-related grade 4 toxicities [4/77 (5.2%)], which consisted of 1 event each of grade 4 thrombocytopenia, thrombotic thrombocytopenic purpura, reversible posterior leukoencephalopathy syndrome, and proteinuria. The most common grade 3 study drug–related toxicities in the overall study population were hypertension (17%), body weight reduction (8%), fatigue (7%), proteinuria (5%), and diarrhea (5%; Table 2). Most grade 3 toxicities were seen in the 5- to 12-mg dose range (5 mg, 71.4%; 8 mg, 56.3%; 12 mg, 71.4%). The incidence of grade 3 hypertension was 86% at 12 mg and 23% at 10 mg (MTD dose); for most patients, these hypertensive events were resolved through either dose adjustments/delays, antihypertensive therapy, or both.

**Response**

The best overall tumor responses evaluated on the basis of RECIST (version 1.0) for patients from the dose-escalation phase and patients from the expanded melanoma cohort are shown in Fig. 1A and B, respectively. Overall, 9 (11.7%) patients achieved confirmed PR. Forty (51.9%) patients had SD, including 19 (24.7%) with SD ≥23 weeks. Eighteen (23.4%) patients experienced PD, 17 by cycle 2. Response was not assessable in 10 (13.0%) patients: 4 withdrew consent after the screening stage, and 6 had events that precluded treatment assessment. The confirmed PRs were most frequent in patients with melanoma (n = 3) and medullary thyroid cancer (n = 3); these PRs were determined after a median of 18 cycles (range, 4–46 cycles). Three patients (2 melanoma, 1 NSCLC) had unconfirmed PRs (uPR), for a total of 12 (15.6%) patients with PR/uPR as their best response.

Of the 18 patients treated on schedule 1, no patient achieved a confirmed PR. Nine (50.0%) had SD (including 1 patient each with breast, hepatocellular, ovarian cancer, or NSCLC who had durable SD ≥23 weeks) and 8 (44.4%) had PD. One patient with NSCLC had a uPR. Of the 33 patients treated on schedule 2, 7 (21.2%) patients achieved a confirmed PR, including 3 with medullary thyroid cancer, 1 with melanoma, and 1 each with ovarian, pancreatic, or renal cell cancer. Fifteen patients (45.5%) had SD; 9 patients had durable SD, including 2 patients with endometrial adenocarcinoma, and 1 patient each with epithelial thymoma, synovial sarcoma, adrenal cortical carcinoma, colon adenocarcinoma, pancreatic cancer, melanoma, or thyroid cancer. Six (18.2%) patients had PD.

Of the 26 patients in the expanded melanoma cohort, 2 (7.7%) achieved a confirmed PR. 16 (61.5%) had SD (including 6 [23.1%] patients who had durable SD ≥23 weeks) and 4 (15.4%) had PD. Two patients in this cohort had uPRs, for a total of 4 patients (15.4%) with PRs/uPRs as their best response.

Twenty-nine patients in the study had melanoma: 3 were on schedule 2 of dose escalation and 26 were in the expanded melanoma cohort. Overall, 3 (10.3%) achieved a PR, 17 (58.6%) had SD (including 7 [24.1%] who had durable SD ≥23 weeks), and 5 (17.2%) had PD. A total of 5 (17.2%) patients with melanoma had PRs/uPRs as their best response.

Figure 1B is a waterfall graph showing response by mutation status in patients from the expanded melanoma cohort. As noted in Table 1, BRAF and NRAS mutations were detected in 9 (34.6%) and 8 (30.8%) patients, respectively. Possibly reflecting the heterogeneity in tumor samples, discordance between the on-site and independent assessment was noted for 2 patients with respect to BRAF mutation status and 1 patient with respect to NRAS mutation status (Fig. 1B inset). Two (7.7%) patients had coexisting mutations were detected in 9 (34.6%) and 8 (30.8%) patients, respectively. Possibly reflecting the heterogeneity in tumor samples, discordance between the on-site and independent assessment was noted for 2 patients with respect to BRAF mutation status and 1 patient with respect to NRAS mutation status (Fig. 1B inset). Two (7.7%) patients had coexisting mutations were detected in 9 (34.6%) and 8 (30.8%) patients, respectively. Possibly reflecting the heterogeneity in tumor samples, discordance between the on-site and independent assessment was noted for 2 patients with respect to BRAF mutation status and 1 patient with respect to NRAS mutation status (Fig. 1B inset). Two (7.7%) patients had coexisting mutations were detected in 9 (34.6%) and 8 (30.8%) patients, respectively. Possibly reflecting the heterogeneity in tumor samples, discordance between the on-site and independent assessment was noted for 2 patients with respect to BRAF mutation status and 1 patient with respect to NRAS mutation status (Fig. 1B inset). Two (7.7%) patients had coexisting
BRAF and NRAS mutations, and 11 (42.3%) patients had both BRAF and NRAS wild-type tumors (Fig. 1B). Three of 17 patients (17.6%) with wild-type BRAF had either PR (n = 2) or uPR (n = 1; Fig. 1B).

**Pharmacokinetics**

Lenvatinib PK parameters are summarized by dose in Table 3. The PK population was equivalent to the overall population (n = 77). Overall, lenvatinib’s single-dose and steady-state PK parameters (Cmax, AUC0–6, and AUC0–24) increased proportionately over the entire dose range evaluated in this study. Median tmax was similar across all dose levels and ranged from 1.5 to 3 hours (excluding the 0.1 and 0.2-mg daily doses at 24 hours and 6 hours of cycle 1 day 1, respectively). The mean terminal elimination half-life (t1/2) has been shown to be approximately 28 to 29 hours in previous phase 1 studies (7, 8). On cycle 2 day 1, the apparent oral clearance was 8.05 and 6.09 L/hour for doses of 8 and 16 mg, respectively. The apparent terminal volume was 86.8 L for the 8-mg dose and 68.5 L for the 16-mg dose. Regardless of dose, the fraction of the lenvatinib dose excreted unchanged in
the urine (fe) during the 24 hours following the dose was low (<1.5%), indicating that excretion via urine is a minor pathway for lenvatinib. A comparison of PK parameters at 8-, 10-, and 12-mg doses after a single dose and at steady state demonstrated relatively low accumulation (approximately 1.5- to 2.2-fold; Fig. 2A). A rapid absorption phase, followed by a distribution phase and then an elimination phase, were generally observed following increasing doses of lenvatinib after a single dose and at steady state (Fig. 2A).

Pharmacodynamics

In the expanded melanoma cohort, changes in NTie-2 levels following lenvatinib treatment correlated with lenvatinib exposure as assessed by AUC_{C21} (Fig. 2B; Spearman correlation R = −0.44, P = 0.005, n = 20) were associated with greater tumor shrinkage (Fig. 3A and B).

In univariate Cox proportional hazard model analyses, higher baseline sBP and dBP were associated with longer PFS (P = 0.004 and P = 0.028, respectively; Supplementary Table S1), whereas acute decreases in angiopoietin-1 (at 2 hours after the first dose of lenvatinib relative to baseline levels) were associated with shorter PFS (P = 0.007; Fig. 3C). Changes from baseline to day 8 in NTie-2, M30, or sBP levels were not found to be associated with PFS outcomes. In a multivariate Cox proportional hazard model analyses, baseline sBP and a ratio of angiopoietin-1 at 2 hours to baseline were significantly associated with PFS (P = 0.041 and P = 0.03, respectively; Supplementary Table S2) using covariates that were identified by univariate analysis (P < 0.01, Supplementary Table S1).

Discussion

In this phase 1 dose-escalation study, the MTD for lenvatinib was established at 10 mg per os twice daily. The drug was well tolerated, with most AEs being those known to be associated with VEGFR inhibition, such as hypertension, fatigue, and proteinuria (15, 16). These were most commonly observed in patients who had received lenvatinib at dose levels >10 mg. Antitumor activity was observed in patients with various solid tumor types, including melanoma, medullary thyroid, non–small cell lung, endometrial, renal, pancreatic, and ovarian. Responses to lenvatinib in patients with medullary thyroid cancer is of special interest, as several multikinase inhibitors have since been granted FDA approval for this indication (17, 18).

Hypertension, fatigue, and proteinuria have been seen with other VEGF inhibitors, including bevacizumab and cediranib (19–21), and are a common side effect of antiangiogenic therapy (22). The incidence of hypertension AEs in the current study (43%) was similar to that in a lenvatinib phase I study of once-daily continuous dosing (40%; ref. 11), but lower than that in a lenvatinib phase I study of twice-daily dosing on an interrupted schedule of 2 weeks on and 1 week off (67%) that explored higher doses (up to 20 mg twice daily; ref. 23). Results from a population PK/PD analysis suggest that active management of side effects, including treatment with antihypertensives for hypertension in association with AE-guided dose de-escalations, may be effective in allowing 80% of patients to continue treatment with lenvatinib for 16 weeks (24).

The incidences of proteinuria (39%) and fatigue (42%) in the current study are largely consistent with those of other studies of lenvatinib administered to patients with solid malignancies (11, 15, 23). Differences observed in a once-daily dosing study (proteinuria, 26%; fatigue, 18%; ref. 11) and in the twice-daily dosing study with higher doses of lenvatinib (proteinuria, 63%; fatigue, 70%; ref. 23) may be attributable, in part, to differences in doses, schedules, and patient populations.

In the current study, 9 patients had confirmed PRs; when patients with uPRs were included as a best response, the proportion was 15.6% (n = 12). The SD rate was 51.9% (40/77 patients), with 19 (24.7%) patients having durable SD for ≥23 weeks. The combined PR/uPR/durable SD rate was 40.3% (31/77 patients). The overall antitumor activity observed in the current study was comparable with antitumor activities observed in other phase 1 studies of lenvatinib (11, 23). The

---

Table 3. Summary of PK parameters by dose level during schedule 2 and at the selected dose of 10 mg twice daily in the melanoma expansion cohort

<table>
<thead>
<tr>
<th>Schedule 2 (continuous daily dosing)</th>
<th>Cycle 1 Day 1</th>
<th>Cycle 2 Day 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose (daily dose)</strong></td>
<td><strong>5.2 mg</strong></td>
<td><strong>10 mg</strong></td>
</tr>
<tr>
<td>N</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>t_{max}, hours^b</td>
<td>2.00 (2.00–2.50)</td>
<td>2.50 (2.00–2.50)</td>
</tr>
<tr>
<td>CL/F, L/hour</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Vss/F, L</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>C_{max}, ng/mL</td>
<td>51.4 (30.5)</td>
<td>62.6 (25.5)</td>
</tr>
<tr>
<td>AUC_{C0,C21}, ng hr/mL</td>
<td>180 (68.6)</td>
<td>245 (115)</td>
</tr>
<tr>
<td>AUC_{C0,24}, ng hr/mL</td>
<td>407.38 (35.7)</td>
<td>649.70 (130.75)</td>
</tr>
<tr>
<td>fe, %</td>
<td>0.37 (0.102)</td>
<td>1.47 (0.685)</td>
</tr>
</tbody>
</table>

^b^ Dose (daily dose) during schedule 2, on PK days cycle 1 day 1 and cycle 2 day 1, only 1 dose of lenvatinib twice daily was administered.

---
combined PR/uPR/durable SD rate (40.3%) is also broadly comparable with that observed with other tyrosine kinase inhibitors in the treatment of advanced solid tumors. For those agents, the rates of PR and sustained SD ranged from 20% to 50%, with the values varying depending on the definition of durable SD (25–29).

The activity of lenvatinib as a single agent in melanoma is encouraging. Three (10.3%) of the 29 patients with melanoma had a confirmed PR and 7 (24.1%) had durable SD. Two melanoma patients had uPRs; therefore, 17.2% of patients with melanoma had at least 30% regression as their best response. Among these responders was a patient with mutant NRAS. The 3 PR/uPR and 8 SDs among the BRAFWt patients are of special interest because currently there are no targeted therapies approved for this patient population.

Melanoma is a highly vascular tumor (30), and angiogenesis plays a crucial role in malignant melanoma (31). Ugurel and colleagues (32) found that serum concentrations of angiogenic factors, such as angiogenin, basic FGF, VEGF, and IL8, were higher in patients with more advanced stages of melanoma, and that

Figure 2.

A, single-dose (cycle 1 day 1) and steady-state (cycle 2 day 1) mean observed plasma lenvatinib concentration vs time curve for dose levels 8 and 12 mg twice daily in schedule 2 and 10 mg twice daily in the expanded melanoma cohort, wherein only 1 dose of the twice-daily dose was administered on cycle 1 day 1 and on cycle 2 day 1. B, association of PK exposure with changes in levels of serum sTie-2 protein on cycle 1 day 8 relative to baseline. Shown here is the correlation between $AUC_{0-24}$ (natural logarithm transformed) and changes in sTie-2 for the expanded melanoma cohort (Spearman correlation $R = -0.45$, $P = 0.0322$; $n = 23$). Each blue dot represents 1 subject; the solid blue line symbolizes the regression line; and the dashed green lines represent 95% confidence limits.

Figure 3.

A, correlation of maximum tumor shrinkage (%) with baseline cytochrome C levels ($n = 22$): Pearson correlation $R = -0.64$, $P = 0.001$; Spearman correlation $R = -0.45$, $P = 0.0368$. B, correlation between maximum tumor shrinkage (%) and M30 C1D8/C1D1 ratio ($n = 20$): Pearson correlation $R = -0.44$, $P = 0.050$; Spearman correlation $R = -0.39$, $P = 0.0894$. Each blue dot represents 1 subject; the solid blue line symbolizes the regression line; and the dashed green lines represent 95% confidence limits. Percent maximum tumor shrinkage was defined as the percentage of reduction in tumor size from baseline to post-baseline nadir. C, Kaplan–Meier survival estimates of PFS, stratified by early changes in angiopoietin-1 levels, in the expanded melanoma cohort ($n = 24$). Subjects were dichotomized by median ratios of angiopoietin-1 levels (2 hours postdose:baseline, $P = 0.007$).
higher serum concentrations of these proangiogenic molecules were associated with diminished OS and PFS. Mehner and colleagues (33) reported higher expression of VEGFR2 in metastases relative to primary tumors, and suggested that angiogenesis is critical to melanoma metastasis. Lenvatinib may exert a greater effect on angiogenesis by targeting multiple signaling pathways, including VEGFR, FGFR, PDGF, RET, and KIT.

The utility of PD biomarkers evaluated in the current study was 2-fold: first, to demonstrate that lenvatinib was engaging the molecular target for which it was designed; and second, to attempt to identify subjects who could maximally benefit from lenvatinib treatment. Pretreatment expression levels of cytochrome C correlated favorably with maximum tumor shrinkage. Cytochrome C induces caspase activation and apoptosis in tumor cells (34). Higher baseline levels of serum cytochrome C may sensitize tumor cells to the apoptotic pathway upon lenvatinib treatment, resulting in greater tumor reduction. Tumor shrinkage was also associated with elevated levels of M30, an antibody that recognizes caspase-cleaved cytokeratin-18, on day 8 relative to day 1 of cycle 1 (35). Cytokeratins are intermediate filament proteins found primarily in epithelial cells (35). Cytokeratin-18 is cleaved by caspas during apoptosis, and thus, elevated caspase-cleaved cytokeratin-18 levels (as indicated by M30) is a measure of increased apoptosis (35). In the current study, the association between an increase in M30 levels between day 8 of cycle 1 (vs. baseline) and greater tumor shrinkage suggests that apoptosis may serve as an indicator of, and potential mechanism for, response with lenvatinib in patients with melanoma.

In this study, decreases in sTie-2 levels at cycle 1 day 8 correlated with lenvatinib exposure. In addition, rapid decreases in serum levels of angiopoietin-1 at 2 hours postlenvatinib treatment relative to baseline were associated with shorter PFS. Although lenvatinib does not directly target the Tie-2 receptor tyrosine kinase, the signaling pathways of both VEGF/VEGFR and angiopoietin/Tie-2 have been shown to be instrumental for tumor angiogenesis, and the angiopoietin-1/Tie-2 signaling network may be associated with antitumor activity of VEGFR signaling inhibitors (36). The relatively small sample size of the current PD analyses limits the ability to draw any conclusions; larger cohorts will be needed to further validate these findings. Importantly, in multivariate Cox proportional hazard model analyses, increased baseline sBP (P = 0.04) and a decreased ratio of angiopoietin-1 at 2 hours versus baseline (P = 0.03) were associated with longer PFS. Other studies have also shown a correlation between BP and antitumor activity across multiple tumor types has prompted the initiation of several phase II and phase III studies of lenvatinib in melanoma, advanced radioiodine-refractory differentiated thyroid cancer, medullary thyroid cancer, hepatocellular carcinoma, endometrial cancer, renal cell carcinoma, and glioblastoma. Biomarker analyses suggest that baseline levels or changes in angiogenesis-related and apoptosis-related markers are associated with PFS in lenvatinib trials. Ongoing phase II and phase III trials will further explore the prognostic and/or predictive utility of these biomarkers in lenvatinib treatment.

**Disclosure of Potential Conflicts of Interest**

D.S. Hong reports receiving a commercial research grant from Eisai, and is a consultant/advisory board member for H3 Biomedicine Inc. R. Kurzrock is a consultant/advisory board member for Sequenom. K.B. Kim is a consultant/advisory board member for Eisai. M.A. Davies reports receiving commercial research grants from Astrazeneca, Genentech/Roche, Glaxosmithkline, Merck, Myriad, Oncothyreon, and Sanofi-Aventis, and is a consultant/advisory board member for Genentech/Roche, Glaxosmithkline, Novartis, and Sanofi-Aventis. No potential conflicts of interest were disclosed by the other authors.

**Authors’ Contributions**

Conception and design: D.S. Hong, C. Andresen, P. Sachdev, J.P. O’Brien

Development of methodology: D.S. Hong, J.P. O’Brien

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): D.S. Hong, J.J. Wheler, A. Naing, G.S. Falchook, S. Fu, K.B. Kim, L.M. Nguyen, J. Mink, C. Bedell

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): D.S. Hong, R. Kurzrock, G.S. Falchook, S. Fu, L.M. Nguyen, G.C. George, L. Xu, R. Shumaker, M. Ren, C. Andresen, P. Sachdev

Writing, review, and/or revision of the manuscript: D.S. Hong, R. Kurzrock, J.J. Wheler, A. Naing, G.S. Falchook, S. Fu, K.B. Kim, M.A. Davies, L.M. Nguyen, G.C. George, L. Xu, R. Shumaker, M. Ren, J. Mink, C. Andresen, P. Sachdev, J.P. O’Brien, J. Nemunaitis

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): D.S. Hong, L.M. Nguyen, G.C. George, J. Mink

Study supervision: D.S. Hong, L.M. Nguyen, J. Mink, C. Andresen, J.P. O’Brien

Other (approval of final draft): R. Kurzrock

Other served as a liaison between MD Anderson and Eisai Inc. during the development of the manuscript: G.C. George

**Acknowledgments**

The authors thank all patients, as well as investigators and their teams, who participated and are participating in this study. The authors also thank Joann Aaron, MA, for scientific editing of the article.

**Grant Support**

This work was supported by Eisai Inc. and by the NIH Clinical and Translational Science Award UCLA CTSA (UL1 RR024148) and NIH Cancer Center Support Grant (CCSG) award CA016672 to MD Anderson Cancer Center. Editorial support was provided by Phase Five Communications and Oxford PharmaGenesis Inc., and was funded by Eisai Inc.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 15, 2015; revised May 12, 2015; accepted June 9, 2015; published OnlineFirst July 13, 2015.

**References**


4. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuunkoa A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of...


29. Dewing D, Emmert M, Priestley Jones J. The roles of angiogenesis in malignant melanoma: trends in basic science research over the last 100 years. ISRN Oncol 2012;2012:546927.


